What does pharmaceuticals — revenue mean?

This metric represents the total gross revenue recognized by the Pharmaceuticals segment from the sale of goods and services to customers under enforceable contracts. It reflects the primary top-line performance of the segment before accounting for any specific tax assessments or deductions. It is a key indicator of market demand and the segment's ability to monetize its pharmaceutical product portfolio.

Baxter International BAX Pharmaceuticals — Revenue

Discontinued — last reported Q4 '20

Similar metrics at other companies

VRTXPharmaceuticals — Product revenues, net

$2.99B+7.8%

IONSProduct — Revenue

$42.96M+583%

AXSMProduct — Revenue

$189.4M+57.4%

CAHPharmaceutical and Specialty Solutions — Revenue

$56.11B+11.3%

ALKSProduct — Revenue

$338.11M+38.3%

CVSPharmacy — Revenues from external customers

$56.94B+8.4%

Other financials

Income statement

See full

Revenue$2.7B+2.9%

Gross profit$891.0M+3.5%

Operating income$66.0M+13.8%

Net income-$15.0M-112%

EPS (diluted)-$0.03-112%

Balance sheet

See full

Cash & equivalents$2.0B-12.1%

Total debt$224.0M-8.9%

Total equity$6.0B-14.7%

Total assets$19.8B-6.8%

Cash flow

See full

Operating cash flow$213.0M+210%

CapEx$128.3M+15.0%

Free cash flow$83.0M-42.1%

Valuation

See full

Market cap$10.27B-50.6%

Enterprise value$8.48B-55.6%

P/S0.9×-1.0×

Profitability

See full

Gross margin30.1%-5.9pp

Operating margin-2.7%—

Net margin-9.7%+62.5pp

FCF margin3%-2.4pp

Returns & leverage

See full

Return on equity-16.7%-76.7pp

Debt / equity0×0.0×

Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The official record: Baxter International’s 10-K, filed February 11, 2021, on SEC EDGAR. View the filing →

Questions, answered.

What does pharmaceuticals — revenue mean?: This metric represents the total gross revenue recognized by the Pharmaceuticals segment from the sale of goods and services to customers under enforceable contracts. It reflects the primary top-line performance of the segment before accounting for any specific tax assessments or deductions. It is a key indicator of market demand and the segment's ability to monetize its pharmaceutical product portfolio.